Femasys (FEMY) Competitors $0.36 0.00 (-1.00%) Closing price 04:00 PM EasternExtended Trading$0.36 +0.01 (+1.49%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. SLNO, APYX, BDMD, VANI, NTRB, CTSO, INO, LUNG, TELA, and SPAIShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), Apyx Medical (APYX), Baird Medical Investment (BDMD), Vivani Medical (VANI), Nutriband (NTRB), Cytosorbents (CTSO), Inovio Pharmaceuticals (INO), Pulmonx (LUNG), TELA Bio (TELA), and Safe Pro Group (SPAI). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors Soleno Therapeutics Apyx Medical Baird Medical Investment Vivani Medical Nutriband Cytosorbents Inovio Pharmaceuticals Pulmonx TELA Bio Safe Pro Group Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the media prefer FEMY or SLNO? In the previous week, Soleno Therapeutics had 15 more articles in the media than Femasys. MarketBeat recorded 22 mentions for Soleno Therapeutics and 7 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 0.91 beat Femasys' score of 0.35 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Soleno Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in FEMY or SLNO? 65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, FEMY or SLNO? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.63M7.13-$18.82M-$0.86-0.41Soleno TherapeuticsN/AN/A-$175.85M-$4.14-16.52 Is FEMY or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,113.72% -713.74% -152.60% Soleno Therapeutics N/A -73.74%-56.67% Which has more volatility and risk, FEMY or SLNO? Femasys has a beta of -2.58, indicating that its share price is 358% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.56, indicating that its share price is 356% less volatile than the S&P 500. Do analysts prefer FEMY or SLNO? Femasys presently has a consensus target price of $7.33, indicating a potential upside of 1,955.88%. Soleno Therapeutics has a consensus target price of $115.09, indicating a potential upside of 68.24%. Given Femasys' higher probable upside, research analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 SummarySoleno Therapeutics beats Femasys on 10 of the 16 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.74M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.4121.0831.2626.59Price / Sales7.13364.13454.13168.41Price / CashN/A44.6737.7359.36Price / Book7.138.0910.046.68Net Income-$18.82M-$54.08M$3.27B$265.59M7 Day Performance-37.15%2.25%3.17%3.42%1 Month Performance-58.77%3.41%4.34%1.09%1 Year Performance-66.03%18.61%44.12%23.84% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys3.1557 of 5 stars$0.36-1.0%$7.33+1,955.9%-66.3%$11.74M$1.63M-0.4130Gap UpSLNOSoleno Therapeutics4.5705 of 5 stars$68.09-4.9%$114.30+67.9%+38.0%$3.81B$32.66M-16.4530News CoverageAnalyst ForecastAPYXApyx Medical2.1759 of 5 stars$2.14-0.9%N/A+49.4%$81.69M$48.10M-4.76270BDMDBaird Medical InvestmentN/A$2.13-6.6%N/AN/A$81.46MN/A0.00N/APositive NewsVANIVivani Medical2.3773 of 5 stars$1.24-0.8%$4.00+222.6%-9.6%$74.06MN/A-2.7620NTRBNutriband3.3343 of 5 stars$6.36-3.2%$13.00+104.4%+15.7%$73.28M$2.14M-7.0710Positive NewsUpcoming EarningsCTSOCytosorbents2.158 of 5 stars$1.10-5.2%$5.50+400.0%-10.6%$72.80M$35.60M-6.47220Positive NewsINOInovio Pharmaceuticals4.0801 of 5 stars$1.90+2.2%$8.80+363.2%-66.9%$68.21M$220K-0.73320Gap UpLUNGPulmonx3.9458 of 5 stars$1.60+2.6%$7.66+379.0%-75.5%$63.56M$83.79M-1.12250TELATELA Bio3.116 of 5 stars$1.70+7.6%$4.50+164.7%-40.1%$62.59M$69.30M-1.52120Positive NewsSPAISafe Pro Group0.3247 of 5 stars$4.06+5.7%$8.00+97.0%N/A$58.26M$2.17M-5.0711 Related Companies and Tools Related Companies Soleno Therapeutics Alternatives Apyx Medical Alternatives Baird Medical Investment Alternatives Vivani Medical Alternatives Nutriband Alternatives Cytosorbents Alternatives Inovio Pharmaceuticals Alternatives Pulmonx Alternatives TELA Bio Alternatives Safe Pro Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access